investors

Press Releases

DateTitle and SummaryView
May 14, 2018
-Continued Progress in Stem-to-T-Cell Program-
-Ongoing Exploration of Strategic Opportunities-
ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results
April 12, 2018
LOS ANGELES , April 12, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular " or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells.
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
March 26, 2018
LOS ANGELES , March 26, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd.  (" ImmunoCellular ") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March
ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation
March 13, 2018
-Continued Progress in Stem-to-T-Cell Program-
-Strengthened Financial Condition-
-Conference Call Today at 5:00 pm ET-
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
March 7, 2018
LOS ANGELES , March 7, 2018 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE American: IMUC) today announced that it plans to report fourth quarter and full year 2017 financial results on Tuesday, March 13, 2018 . The Company also plans to hold a conference call and
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
February 22, 2018
LOS ANGELES , Feb. 22, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has retained Ladenburg
ImmunoCellular Therapeutics Announces Review of Strategic Alternatives
February 13, 2018
Strengthened Financial Condition Supports Continued Advancement of Stem-to-T-Cell Program
ImmunoCellular Therapeutics Announces Update on Financial Condition
December 13, 2017
Completes Important First Step toward Production of Unlimited Killer T Cells Designed to Attack Cancer Cells
ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
November 22, 2017
Live presentation will take place on December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET)
ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017
November 21, 2017
-Continued Focus on Stem-to-T-Cell Program-
-Strengthened Financial Condition-
-Conference Call Today at 5:00 pm ET-
ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved